Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

@article{Fontana2016DaclatasvirCW,
  title={Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.},
  author={Robert J Fontana and Robert S Brown and Ana Moreno-Zamora and M E Herrero Prieto and Shobha N Joshi and Mar{\'i}a Carlota Londo{\~n}o and Kerstin Herzer and Kristina Rachel Chacko and Rudolf E. Stauber and Viola Knop and S Rafaqt Ali Jafri and Llu{\'i}s Castells and P Ferenci and Carlo Torti and Christine M Durand and Laura Loiacono and Raffaella Lionetti and Ranjeeta Bahirwani and Ola Weiland and Abdullah Mubarak and Ahmed ElSharkawy and Bernhard Stadler and Marzia Montalbano and Christoph Peter Berg and Adriano Maria Pellicelli and Stephan Stenmark and Francis Vekeman and Raluca Ionescu-Ittu and Bruno Emond and K Rajender Reddy},
  journal={Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society},
  year={2016},
  volume={22 4},
  pages={446-58}
}
Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or simeprevir (SMV) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection. Herein, we report efficacy and safety data for DCV-based all-oral antiviral therapy in liver transplantation (LT) recipients with severe recurrent HCV. DCV at 60 mg/day was administered for up to 24 weeks as part of a compassionate use… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…